Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $37.0 million.

  • Ultragenyx Pharmaceutical's Share-based Compensation fell 10.97% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.7 million, marking a year-over-year increase of 2.72%. This contributed to the annual value of $158.1 million for FY2024, which is 16.88% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Share-based Compensation is $37.0 million, which was down 4.16% from $38.6 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Share-based Compensation ranged from a high of $41.6 million in Q3 2024 and a low of $24.3 million during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $37.0 million (2025), whereas its average is $37.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 32.69% in 2021, then declined by 10.97% in 2025.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Share-based Compensation stood at $26.5 million in 2021, then climbed by 10.57% to $29.4 million in 2022, then grew by 14.95% to $33.7 million in 2023, then grew by 19.10% to $40.2 million in 2024, then declined by 10.97% to $37.0 million in 2025.
  • Its Share-based Compensation was $37.0 million in Q3 2025, compared to $38.6 million in Q2 2025 and $39.9 million in Q1 2025.